BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

Zealand Pharma And OTR Therapeutics Forge Strategic Collaboration To Advance Next Generation Metabolic Therapies

Collaboration will combine Zealand Pharma's expertise in obesity and metabolic health with OTR Therapeutics' proprietary oral small-molecule platform and...

December 12, 2025 | News

Formation Bio Acquires Global Rights To CNS Penetrant TYK2 Inhibitor LNK01006

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals") and Formation Bio announced Formation Bio's acquisition of wor...

December 11, 2025 | News

D3 Bio Secures One Hundred 8M$ In Series B Funding To Advance Global Late Stage Oncology Trials

D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completio...

December 11, 2025 | News

Innovent Doses First Participant in Phase One Trial of Novel IL One RAP Antibody for Gout

Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment ...

December 11, 2025 | News

Fosun Pharma And Pfizer Enter Global GLP One Receptor Agonist Licensing Deal For YP05002

Fosun Pharma announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Devel...

December 10, 2025 | News

Innovent Biologics Seven Innovative Therapies Included in China’s 2025 National Reimbursement Drug List

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high qual...

December 08, 2025 | News

Biocytogen Announces FDA IND Clearance for IDE034 Bispecific B7H3 PTK7 ADC Licensed to IDEAYA Biosciences

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision o...

December 08, 2025 | News

Kelun Biotech And Crescent Biopharma Forge Global Partnership To Advance Next Generation Oncology Therapies

Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets an...

December 05, 2025 | News

Antengene Secures Expanded Approvals For Xpovio In Hong Kong Across Multiple Myeloma And DLBCL

- XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the treatment for mul...

December 04, 2025 | News

Amaran Biotech Achieves FDA Acknowledgement for Type II DMF of AB801 Vaccine Adjuvant

Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), announced that its self-developed, GMP-grade high-purity vacc...

December 03, 2025 | News

Antengene Secures NMPA Approval for IND of CLINCH Two Combination Study in Gastric Cancer

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, develop...

December 03, 2025 | News

Imugene and JW Therapeutics Launch First-in-Class “Mark and Kill” Solid Tumor Collaboration

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytic...

December 01, 2025 | News

Juventas’ CAR-T Therapy Ina-cel Receives NMPA Approval for Large B-Cell Lymphoma

Juventas Cell Therapy Co., Ltd. (hereinafter referred to as "Juventas") announced that its independently developed CAR-T cell therapy product, Inatica...

December 01, 2025 | News

BioDlink Drives Global Biologics Innovation with World’s First Approved EGFR-Targeted ADC

Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyng...

December 01, 2025 | News

Stay Connected